Get my own profile
Public access
View all85 articles
10 articles
available
not available
Based on funding mandates
Co-authors
- Nitash P. BalsaraUniversity of California, Berkeley, and Lawrence Berkeley National LaboratoryVerified email at berkeley.edu
- Kent KirshenbaumProfessor of Chemistry, New York UniversityVerified email at nyu.edu
- Rachel SegalmanEdward Noble Kramer Professor of Materials, UCSBVerified email at ucsb.edu
- Ken A. DillDirector of Laufer Center, Stony Brook UniversityVerified email at laufercenter.org
- F E CohenUCSFVerified email at pacbell.net
- Walter H MoosUCSF, Pandect Bioventures, ShangPharma Innovation, SRI, MitoKor, Chiron, Warner-Lambert/Parke-DavisVerified email at ucsf.edu
- Sunting XuanSoochow UniversityVerified email at suda.edu.cn
- Xi JiangLawrence Berkeley National LaboratoryVerified email at lbl.gov
- Eric J. MartinNovartisVerified email at novartis.com
- Ryan K SpencerProtomer Technologies, a wholly-owned subsidiary of Eli Lilly and companyVerified email at uci.edu
- Stephen WhitelamStaff Scientist, Lawrence Berkeley National LabVerified email at lbl.gov
- David PrendergastMolecular Foundry, Lawrence Berkeley National LaboratoryVerified email at lbl.gov
- Caroline ProulxNorth Carolina State UniversityVerified email at ncsu.edu
- Helen TranUniversity of TorontoVerified email at utoronto.ca
- Glenn ButterfossProteinQureVerified email at proteinqure.com
- Babak SaniiNutcracker TherapeuticsVerified email at nutcrackerx.com
- Adrianne RosalesAssociate Professor, University of Texas at AustinVerified email at che.utexas.edu
- Ranjan MannigeCerevel TherapeuticsVerified email at lbl.gov
- Ki Tae NamProfessor, Department of Materials Science and Engineering, Seoul National UniversityVerified email at snu.ac.kr
- Deborah CharychNektar TherapeuticsVerified email at nektar.com
Follow
Ronald N. Zuckermann
Molecular Foundry, Lawrence Berkeley National Laboratory
Verified email at lbl.gov - Homepage